Fifth DSMB Meeting Supports Neurobiological Technologies’ Continuation Of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), announced that after a scheduled review, an independent data safety monitoring board (DSMB) has recommended continuation of the company’s two Phase 3 clinical trials to determine whether a brief intravenous infusion of Viprinex(TM) (ancrod) started within 6 hours of stroke onset improves functional outcome at 3 months. This is the fifth DSMB meeting for the Ancrod Stroke Program (ASP).
More: continued here
Filed under: Stroke on May 15th, 2008